A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

摘要

Inhibition of cyclin-dependent kinases (CDKs) is a promising strategy for mantle cell lymphoma (MCL). We conducted a phase II study of P276-00, a small molecule inhibitor of several CDK isoforms, in patients with relapsed or refractory MCL. Although relatively well-tolerated, no objective responses were seen. Future studies with this agent should consider it in new schedules or combined with other treatments.